CADL
Candel Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CADL
Candel Therapeutics, Inc.
A late clinical stage biopharmaceutical company that develops novel oncolytic viral immunotherapies
117 Kendrick St Suite 450, Needham, MA 02494
--
Candel Therapeutics, Inc., was incorporated in Delaware in June 2003. The company is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that trigger individualized, systemic anti-tumor immune responses to help patients fight cancer.
Company Financials
EPS
CADL has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.17, missing expectations. The chart below visualizes how CADL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
